間質性肺病（ILD）市場規模、佔有率和成長分析：按疾病類型、治療類型、給藥途徑、最終用戶、分銷管道和地區分類 - 2026-2033 年行業預測

2024 年全球間質性肺病 (ILD) 市場價值為 96.2 億美元，預計到 2025 年將成長至 103.7 億美元，到 2033 年將成長至 189.2 億美元，在預測期（2026-2033 年）內複合年成長率為 7.8%。

全球間質性肺病 (ILD) 市場成長的主要驅動力是纖維性肺病（尤其是特發性肺纖維化）盛行率的不斷上升，而這種疾病的流行與人口老化和污染物暴露的增加密切相關。該市場涵蓋旨在延緩疾病進展和提高患者生活品質 (QOL) 的診斷、治療和護理技術。隨著早期檢測的普及，市場正從症狀治療轉向抗纖維化藥物治療，一些顯著提高存活率的藥物獲批正在深刻改變治療實踐。個人化醫療的快速發展至關重要，它能夠實現一對一治療，從而改善治療效果並提高成本效益。此外，人工智慧的進步正在革新藥物研發，加速標靶識別和臨床試驗，促進創新療法融入 ILD 治療管線，並加強業內各領域專家之間的合作。

全球間質性肺病（ILD）市場促進因素

民眾和醫療專業人員對間質性肺病的認知不斷提高，促使症狀能夠更早被發現，患者也能更快接受醫療評估。這種認知的提高推動了診斷諮詢量的增加，也促使臨床醫師探索新的治療方法，從而增加了對治療方案的需求。此外，這種認知的提升也促進了相關計劃工作，推動了支持研究經費和報銷機制的政策制定。因此，患者參與臨床試驗的比例顯著增加，創新解決方案的接受度也不斷提高。這些因素共同促進了全球醫療保健領域製藥和診斷行業的強勁成長。

全球間質性肺病（ILD）市場面臨的限制因素

由於新療法的高昂成本，間質性肺病 (ILD) 市場面臨嚴峻挑戰，這給患者、保險公司和醫療服務提供者都帶來了經濟障礙。不斷飆升的治療費用常常導致治療啟動延遲、處方療程受限或因病情嚴重程度而限制用藥，最終阻礙市場成長。支付方通常會實施嚴格的核准流程，而保險覆蓋不足的患者可能選擇完全放棄治療。這種經濟負擔降低了銷量，阻礙了創新療法的廣泛應用，導致儘管這些療法具有潛在的臨床效益，但整體市場擴張卻停滯不前。

全球間質性肺病（ILD）市場趨勢

全球間質性肺病 (ILD) 市場正經歷著變革性趨勢，而精準診斷技術的進步正是推動這一趨勢的關鍵因素。高解析度成像和基因組分析的融合提高了 ILD 亞型識別的準確性，從而促進了早期發現和標靶治療的選擇。隨著專業實驗室和數位化平台的不斷擴展，臨床醫生正透過非侵入性方法獲得可操作的見解，這增強了他們對個人化治療方案的信心。為了應對這一轉變，製藥公司正將其研發策略轉向生物標記驅動的方法，從而加速藥物開發週期，並為全球不同患者群體創造新的治療機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球間質性肺病 (ILD) 市場規模：依疾病類型分類

• 特發性肺纖維化
• 過敏性肺炎
• 與結締組織疾病相關的間質性肺病
• 類肉瘤病
• 其他間質性肺病

全球間質性肺病 (ILD) 市場規模：按治療類型分類

• 抗纖維化藥物
• 免疫抑制劑
• 氧氣療法
• 肺移植

全球間質性肺病（ILD）市場規模：依給藥途徑分類

• 口服
• 靜脈
• 吸入

全球間質性肺病 (ILD) 市場規模：按最終用戶分類

• 醫院
• 專科診所
• 居家照護

全球間質性肺病 (ILD) 市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球間質性肺病（ILD）市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche Holding AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Hoffmann-La Roche Ltd.
• United Therapeutics Corporation
• Galapagos NV
• Gilead Sciences, Inc.
• AstraZeneca PLC
• Novartis AG
• Sanofi SA
• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• Fresenius SE & Co. KGaA
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd.
• CH Boehringer Sohn AG & Co. KG
• Insmed Incorporated

結論與建議

Global Interstitial Lung Disease (Ild) Market size was valued at USD 9.62 Billion in 2024 and is poised to grow from USD 10.37 Billion in 2025 to USD 18.92 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The global interstitial lung disease (ILD) market is being driven by an increasing prevalence of fibrotic lung conditions, particularly idiopathic pulmonary fibrosis, among aging populations and rising pollutant exposure. This market encompasses diagnostics, therapeutics, and care technologies aimed at slowing disease progression and improving patient quality of life. Emphasizing early detection, the market has transitioned from supportive treatments to antifibrotic agents, significantly altering therapeutic practices with notable drug approvals that enhance survival. The surge in personalized medicine is pivotal, allowing tailored treatment that improves outcomes and justifies costs. Furthermore, advancements in AI are revolutionizing drug discovery by expediting target identification and clinical trials, facilitating the integration of innovative therapies into the ILD pipeline, and fostering collaboration among various experts within the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Interstitial Lung Disease (Ild) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Interstitial Lung Disease (Ild) Market Segments Analysis

Global interstitial lung disease (ild) market is segmented by disease type, treatment type, route of administration, end user, distribution channel and region. Based on disease type, the market is segmented into Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Connective Tissue Disease-Associated ILD, Sarcoidosis and Other Interstitial Lung Diseases. Based on treatment type, the market is segmented into Antifibrotic Drugs, Immunosuppressive Drugs, Oxygen Therapy and Lung Transplantation. Based on route of administration, the market is segmented into Oral, Intravenous and Inhalation. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Homecare. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Interstitial Lung Disease (Ild) Market

The expanding awareness of interstitial lung disease among both the public and healthcare professionals is leading to earlier recognition of symptoms, motivating patients to pursue medical evaluation more promptly. This increased awareness results in a higher number of diagnostic consultations and a growing demand for treatment options as clinicians explore new therapies. Furthermore, heightened awareness fosters advocacy movements that promote policies supporting research funding and reimbursement mechanisms. As a result, there is a marked rise in patient participation in clinical trials and wider acceptance of innovative solutions, which collectively contribute to a robust growth trajectory for both pharmaceutical and diagnostic sectors within the global healthcare framework.

Restraints in the Global Interstitial Lung Disease (Ild) Market

The interstitial lung disease (ILD) market faces considerable challenges due to the high costs linked with new therapies, which create financial obstacles for patients, insurers, and healthcare providers. These elevated treatment expenses frequently result in delayed treatment initiation, restricted prescription lengths, or limited use based on the severity of the condition, ultimately hindering market growth. Payers often implement strict prior-authorization processes, while patients lacking sufficient insurance coverage might opt to skip therapies entirely. This economic strain diminishes sales volume and impairs the widespread adoption of innovative treatments, thereby stalling the overall expansion of the market, despite the potential clinical benefits offered by these therapies.

Market Trends of the Global Interstitial Lung Disease (Ild) Market

The Global Interstitial Lung Disease (ILD) market is witnessing a transformative trend driven by advancements in precision diagnostics. The integration of high-resolution imaging and genomic profiling is enhancing the accuracy of ILD subtype identification, facilitating earlier detection and targeted therapy selection. As specialty laboratories and digital platforms continue to expand, clinicians are gaining non-invasive access to actionable insights, which boosts their confidence in personalized treatment pathways. This shift has prompted pharmaceutical companies to adjust their research and development strategies towards biomarker-oriented approaches, leading to accelerated drug development cycles and the emergence of new therapeutic opportunities tailored to diverse global patient populations.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Interstitial Lung Disease (ILD) Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Idiopathic Pulmonary Fibrosis
• Hypersensitivity Pneumonitis
• Connective Tissue Disease-Associated ILD
• Sarcoidosis
• Other Interstitial Lung Diseases

Global Interstitial Lung Disease (ILD) Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Antifibrotic Drugs
• Immunosuppressive Drugs
• Oxygen Therapy
• Lung Transplantation

Global Interstitial Lung Disease (ILD) Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Inhalation

Global Interstitial Lung Disease (ILD) Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare

Global Interstitial Lung Disease (ILD) Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Interstitial Lung Disease (ILD) Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C.H. Boehringer Sohn AG & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations